Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Janux Therapeutics Q3 2026 Results: Net Loss of $21.6M, Loss Narrows

Janux Therapeutics reported a net loss of $21.6 million for the third quarter of 2026, an improvement from the $24.3 million loss in the prior year period. The company maintains a strong liquidity position with $945.7 million in cash, cash equivalents, and short-term investments as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue9.310.0
Net income-21.6-24.3
EPS (diluted, $ a share)$-0.34$-0.39

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-7.1%
Operating margin-336.5%
Source

10-Q filed with the SEC, NASDAQ: JANX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Janux Therapeutics, Inc.: key numbers

Share price
$10.71Close, Nov 17
Market cap
$655M
Shares outstanding
61.18MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Janux Therapeutics, Inc.

All →
4:11 PM ET 8-K
Financial Results

Janux Therapeutics Financial Results

Janux Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a strong cash position of $945.7 million. The company continues to advance its clinical pipeline, including dosing the first patient in a Phase 1 study of JANX013 and preparing for an upcoming data presentation for JANX011.

“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007. We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”

David Campbell, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.